← Back to Clinical Trials
Recruiting Phase 4 NCT06406010

NCT06406010 Investigating the Effect of Pericapsular Nerve Group (PENG) Block on Postoperative Pain After Peri-acetabular Osteotomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06406010
Status Recruiting
Phase Phase 4
Sponsor Matias Vested
Condition Anesthesia, Local
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2024-08-19
Primary Completion 2026-02-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Ropivacaine 5mg/ml 20mlSaline 0.9%

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 90 participants in total. It began in 2024-08-19 with a primary completion date of 2026-02-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to determine the effect of PENG blockade on postoperative pain after either ropivacaine 5 mg/mL or saline (placebo) in patients undergoing PAO. The hypothesis of this study is that PENG block with ropivacaine reduces postoperative pain compared to placebo (saline).

Eligibility Criteria

Inclusion Criteria: 1. Patients ≥ 18 years old 2. Informed consent 3. Scheduled for periacetabular osteotomy under general anesthesia with intubation 4. American Society of Anesthesiologists (ASA) physical status classification I to III 5. Can read and understand Danish Exclusion Criteria: 1. Known allergy to ropivacaine 2. Daily use of opioids, gabapentin or tricyclic antidepressant (regardless of dose) within the last four weeks prior to surgery 3. Contraindications to Celocoxib, NSAIDs or paracetamol

Contact & Investigator

Central Contact

Matias Vested

✉ matias.vested@regionh.dk

📞 +4535455747

Principal Investigator

Matias Vested, Md, PhD

STUDY CHAIR

Rigshospitalet University of Copenhagen

Frequently Asked Questions

Who can join the NCT06406010 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Anesthesia, Local. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06406010 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT06406010 currently recruiting?

Yes, NCT06406010 is actively recruiting participants. Contact the research team at matias.vested@regionh.dk for enrollment information.

Where is the NCT06406010 trial being conducted?

This trial is being conducted at Copenhagen, Denmark.

Who is sponsoring the NCT06406010 clinical trial?

NCT06406010 is sponsored by Matias Vested. The principal investigator is Matias Vested, Md, PhD at Rigshospitalet University of Copenhagen. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology